Brokerages Set aTyr Pharma Inc (NASDAQ:LIFE) Price Target at $1.01

Share on StockTwits

aTyr Pharma Inc (NASDAQ:LIFE) has been given a consensus recommendation of “Hold” by the six ratings firms that are currently covering the stock, Marketbeat reports. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $1.01.

A number of equities research analysts have recently weighed in on the stock. ValuEngine upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. William Blair reiterated a “market perform” rating on shares of aTyr Pharma in a research report on Tuesday, March 26th. Finally, Zacks Investment Research upgraded shares of aTyr Pharma from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research report on Friday, March 29th.

Shares of NASDAQ LIFE traded down $0.03 during midday trading on Monday, reaching $0.35. The company’s stock had a trading volume of 809,070 shares, compared to its average volume of 399,966. The company has a current ratio of 4.00, a quick ratio of 4.00 and a debt-to-equity ratio of 0.31. aTyr Pharma has a fifty-two week low of $0.31 and a fifty-two week high of $1.37. The stock’s 50 day moving average price is $0.49. The firm has a market cap of $15.47 million, a P/E ratio of -0.30 and a beta of 2.59.

aTyr Pharma (NASDAQ:LIFE) last released its quarterly earnings results on Monday, May 13th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05.

aTyr Pharma Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.

Featured Story: What does the Producer Price Index (PPI) tell investors?

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Analyzing Puma Biotechnology  and Ionis Pharmaceuticals
Analyzing Puma Biotechnology and Ionis Pharmaceuticals
Head-To-Head Review: Atento  and VIVENDI SA/ADR
Head-To-Head Review: Atento and VIVENDI SA/ADR
Retail Opportunity Investments  and City Office REIT  Critical Survey
Retail Opportunity Investments and City Office REIT Critical Survey
Analyzing StoneMor Partners  & Verb Technology
Analyzing StoneMor Partners & Verb Technology
Financial Review: Cronos Group  & Aurora Cannabis
Financial Review: Cronos Group & Aurora Cannabis
KBL MERGER CORP/SH  vs. Verra Mobility  Head to Head Contrast
KBL MERGER CORP/SH vs. Verra Mobility Head to Head Contrast


© 2006-2019 Ticker Report